# Kidney Cancer (Renal Cell Carcinoma) Pathways

<table>
<thead>
<tr>
<th>Patient Name: ____________________________</th>
<th>Date of Birth: ____________________________</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member Number: __________________________</td>
<td>Treatment Start Date: ______________________</td>
</tr>
<tr>
<td>Pathology: ______________________________</td>
<td>Stage: ____________________</td>
</tr>
</tbody>
</table>
| **Line of Therapy:** __Neoadjuvant/Pre-Op__ __Adjuvant/Post-Op__  
  __1st Line__ __2nd Line__ __3rd Line__ __3rd Line+__ | **ECOG Performance Status:** ______  **ICD-10 Code:** ____________ |
| **Biomarkers/Characteristics:** (Select all that apply)  
  Microsatellite Instability: __dMMR/MSI-H__ __MSI-L__ __Not Reported__  
  Renal Cancer Risk: __Poor__ __Intermediate__ __Good__  
  NTRK Fusion: __Negative__ __Positive__ __Not Reported__  
  Prior Therapy: ______________________________ |

## Metastatic Disease | First Line of Therapy (1st Line) | Clear Cell Carcinoma

- __Nivolumab (Opdivo) and ipilimumab (Yervoy)__
- __Pembrolizumab (Keytruda) and axitinib (Inlyta)__

## Metastatic Disease | Second or Subsequent Lines of Therapy (2nd Line+) | Clear Cell Carcinoma

- __Nivolumab (Opdivo)__

---

**Note:** Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.